Pith. sign in

REVIEW 8 cited by

De novo design of high-affinity protein binders with AlphaProteo

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2409.08022 v1 pith:76AVMZFY submitted 2024-09-12 q-bio.BM

De novo design of high-affinity protein binders with AlphaProteo

classification q-bio.BM
keywords alphaproteodesignbindersproteinsexperimentalhigh-affinitymethodsnovo
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
Share X Bluesky LinkedIn Reddit HN
read the original abstract

Computational design of protein-binding proteins is a fundamental capability with broad utility in biomedical research and biotechnology. Recent methods have made strides against some target proteins, but on-demand creation of high-affinity binders without multiple rounds of experimental testing remains an unsolved challenge. This technical report introduces AlphaProteo, a family of machine learning models for protein design, and details its performance on the de novo binder design problem. With AlphaProteo, we achieve 3- to 300-fold better binding affinities and higher experimental success rates than the best existing methods on seven target proteins. Our results suggest that AlphaProteo can generate binders "ready-to-use" for many research applications using only one round of medium-throughput screening and no further optimization.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 8 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. A-CODE: Fully Atomic Protein Co-Design with Unified Multimodal Diffusion

    q-bio.QM 2026-05 unverdicted novelty 8.0

    A-CODE presents a fully atomic one-stage multimodal diffusion model for protein co-design that claims superior unconditional generation performance over prior one- and two-stage models plus a tenfold success-rate gain...

  2. ProtDBench: A Unified Benchmark of Protein Binder Design and Evaluation

    q-bio.QM 2026-05 unverdicted novelty 7.0

    ProtDBench is a new evaluation benchmark that standardizes protein binder design assessment, reveals verifier-dependent bias in structure predictors, and compares generative methods under fixed 24-hour and diversity-a...

  3. Chamaileon: Cross-Context Binder Design with Contextualized Modeling and Mixed Sampling

    cs.LG 2026-07 conditional novelty 6.5

    I3CD plus MoPS sampling produces single binder sequences that AlphaFold-Multimer scores as compatible with multiple conformational or multi-target contexts on the CROSS benchmark.

  4. Accurate structural modeling of chemically diverse molecular interfaces with Vilya-2

    cs.LG 2026-07 conditional novelty 6.0

    Vilya-2 predicts bound structures of chemically diverse peptides and small molecules at state-of-the-art accuracy using an all-atom diffusion transformer, recovering 59.1% of peptide interfaces to sub-2 Å backbone RMSD.

  5. ProtDBench: A Unified Benchmark of Protein Binder Design and Evaluation

    q-bio.QM 2026-05 unverdicted novelty 6.0

    ProtDBench standardizes protein binder design evaluation using wet-lab data, exposing verifier biases, metric dependencies, and trade-offs between success rate, speed, and structural diversity.

  6. Proteo-R1: Reasoning Foundation Models for De Novo Protein Design

    cs.LG 2026-05 unverdicted novelty 6.0

    Proteo-R1 decouples an MLLM-based understanding expert that selects functional residues from a diffusion-based generation expert that builds protein structures under those explicit constraints.

  7. Towards an AI co-scientist

    cs.AI 2025-02 unverdicted novelty 6.0

    A multi-agent AI system generates novel biomedical hypotheses that show promising experimental validation in drug repurposing for leukemia, new targets for liver fibrosis, and a bacterial gene transfer mechanism.

  8. ADIOS: Antibody Development via Opponent Shaping

    q-bio.PE 2024-09 conditional novelty 6.0

    ADIOS applies opponent shaping in a meta-learning setup to create antibodies that target current and future viral variants while biasing evolution toward weaker strains, demonstrated in Absolut! simulations.